We strive resolve issues in the ineffective treatment of cancer patients through personalization of treatment. Based on the hollow fiber assay developed by US NCI, and combined with Microtube Array Membrane (MTAM), our technique MTAM-HFA delivers screening solutions for personalized cancer treatment and commercial anti-cancer drug R&D. Compared to the gold standard-PDX, our screening brings accuracy and translatability, at a fraction time (14 days) and cost (up to 80% reduction) of conventional PDX. More importantly, MTAM-HFA is capable of screening a large variety of cancer types and anti-cancer drugs, including immunotherapy; conferring unprecedented value to patients alike.